Palmer Medical is a pulmonary arterial hypertension technology development platform. The self-developed radiofrequency ablation catheter for the treatment of pulmonary hypertension has obtained the FDA Breakthrough Designation qualification. Previously, Palmer Medical has completed the PADN-CFDA clinical trial. All are enrolled, and will continue to assist each enrolled center to complete the follow-up of enrolled patients and other follow-up work. Recently, Pamu Medical completed a new round of financing of tens of millions of dollars. This round of financing was led by Yuansheng Ventures, with participation from OrbiMed, Qianji Capital, Lilly Asia Fund (LAV), Gaorong Capital, Huihe Capital, and GC&H Investments. All the old shareholders were oversubscribed. China Renaissance served as the exclusive financial advisor for this round of financing.
This article is reproduced from: https://www.itjuzi.com/investevent/13645595
This site is for inclusion only, and the copyright belongs to the original author.